Newborn Screening for Mucopolysaccharidosis Type II in Illinois: An Update
Open Access
- 3 September 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 6 (3), 73
- https://doi.org/10.3390/ijns6030073
Abstract
Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is a rare, progressive multisystemic lysosomal storage disorder with significant morbidity and premature mortality. Infants with MPS II develop signs and symptoms of the disorder in the early years of life, yet diagnostic delays are very common. Enzyme replacement therapy is an effective treatment option. It has been shown to prolong survival and improve or stabilize many somatic manifestations of the disorder. Our initial experience with newborn screening in 162,000 infants was previously reported. Here, we update that experience with the findings in 339,269 infants. Measurement of iduronate-2-sulfatase (I2S) activity was performed on dried blood spot samples submitted for other newborn screening disorders. A positive screen was defined as I2S activity less than or equal to 10% of the daily median. In this series, 28 infants had a positive screening test result, and four other infants had a borderline result. Three positive diagnoses of MPS II were established, and 25 were diagnosed as having I2S pseudodeficiency. The natural history and the clinical features of MPS II make it an ideal target for newborn screening. Newborn screening was effective in identifying affected infants in our population with an acceptable rate of false positive results.Keywords
This publication has 17 references indexed in Scilit:
- 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatmentBMC Medical Genetics, 2016
- Enhanced diagnostic yield in Meckel-Gruber and Joubert syndrome through exome sequencing supplemented with split-read mappingBMC Medical Genetics, 2016
- Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better OutcomesThe Journal of Pediatrics, 2015
- Enzyme Replacement Therapy in Mucopolysaccharidosis II Patients Under 1 Year of AgeJIMD Reports, 2014
- Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: Comparison in two siblingsMolecular Genetics and Metabolism, 2013
- Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: A nationwide survey in JapanMolecular Genetics and Metabolism, 2012
- Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfallsEuropean Journal of Pediatrics, 2012
- Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): Data from the Hunter Outcome SurveyGenetics in Medicine, 2010
- Cumulative incidence rates of the mucopolysaccharidoses in GermanyJournal of Inherited Metabolic Disease, 2005
- Incidence of the mucopolysaccharidoses in Western AustraliaAmerican Journal of Medical Genetics Part A, 2003